Home » EU-Japan Float Criteria for Developing Drugs Using Block-Copolymer-Micelles
EU-Japan Float Criteria for Developing Drugs Using Block-Copolymer-Micelles
February 11, 2013
First-in-human studies of block-copolymer-micelle (BCM) drug products should establish sampling time points and sampling duration that quantify the time course of the nanotech products for total active substance, free active substance and metabolites, according to a joint EU-Japan reflection paper.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor